Alkermes (ALKS) Stock Forecast & Price Target

Compare

522 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Moderate Buy

8 Buy

6 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$39.79

▲(27.78%Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $39.79 with a high forecast of $52.00 and a low forecast of $30.00. The average price target represents a 27.78% change from the last price of $31.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","53":"$53","29.75":"$29.8","37.5":"$37.5","45.25":"$45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,29.75,37.5,45.25,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.29,32.88307692307692,34.47615384615384,36.06923076923077,37.66230769230769,39.255384615384614,40.848461538461535,42.44153846153846,44.034615384615385,45.62769230769231,47.22076923076923,48.81384615384616,50.40692307692308,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.29,31.943846153846152,32.597692307692306,33.25153846153846,33.90538461538461,34.559230769230766,35.213076923076926,35.86692307692307,36.52076923076923,37.174615384615386,37.82846153846154,38.48230769230769,39.136153846153846,{"y":39.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.29,31.19076923076923,31.091538461538462,30.99230769230769,30.893076923076922,30.793846153846154,30.694615384615386,30.595384615384614,30.496153846153845,30.396923076923077,30.29769230769231,30.198461538461537,30.09923076923077,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.01,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.39,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$39.79

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$35

Buy

12.40%

Upside

Reiterated

05/31/25

Alkermes benefits from strong financial fundamentals, positive earnings call insights, and supportive corporate events. Technicals are stable but not overly bullish, and valuation metrics are fair. The main risks are revenue growth consistency and market dependency.

Joseph ThomeTD Cowen

TD Cowen

$38

Buy

22.03%

Upside

Reiterated

06/03/25

TD Cowen Remains a Buy on Alkermes (ALKS)

David AmsellemPiper Sandler

Piper Sandler

$38

Buy

22.03%

Upside

Reiterated

05/29/25

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Ami FadiaNeedham

Needham

$45

Buy

44.51%

Upside

Initiated

05/28/25

Alkermes Poised for Growth with Promising ALKS 2680 and Strategic Pipeline Expansion

Uy EarMizuho Securities

Mizuho Securities

$40

Buy

28.45%

Upside

Reiterated

05/23/25

Mizuho Securities Reaffirms Their Buy Rating on Alkermes (ALKS)

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$42

Buy

34.87%

Upside

Reiterated

05/14/25

Stifel Nicolaus Keeps Their Buy Rating on Alkermes (ALKS)

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

$43

Buy

38.09%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Joel BeattyRobert W. Baird

Robert W. Baird

$38→$41

Buy

31.66%

Upside

Reiterated

05/02/25

Alkermes price target raised to $41 from $38 at BairdAlkermes price target raised to $41 from $38 at Baird

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$46

Hold

47.72%

Upside

Reiterated

05/02/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN) and Alkermes (NASDAQ: ALKS)

Jason GerberryBank of America Securities

Bank of America Securities

$35

Hold

12.40%

Upside

Reiterated

05/01/25

Alkermes Hold Rating: Balancing Orexin Program Prospects and Competitive Risks

Marc GoodmanLeerink Partners

Leerink Partners

$30

Hold

-3.66%

Downside

Reiterated

05/01/25

Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (NASDAQ: ALHC), Alkermes (NASDAQ: ALKS) and Summit Therapeutics (NASDAQ: SMMT)

Leonid TimashevRBC Capital

RBC Capital

$39→$40

Hold

28.45%

Upside

Reiterated

05/01/25

RBC Capital Keeps Their Hold Rating on Alkermes (ALKS)

Ashwani VermaUBS

UBS

$38→$33

Hold

5.97%

Upside

Reiterated

04/28/25

Alkermes price target lowered to $33 from $38 at UBSAlkermes price target lowered to $33 from $38 at UBS

David HoangDeutsche Bank

Deutsche Bank

$40→$52

Buy

66.99%

Upside

Reiterated

03/27/25

Alkermes price target raised to $52 from $40 at Deutsche BankAlkermes price target raised to $52 from $40 at Deutsche Bank

Jessica FyeJ.P. Morgan

J.P. Morgan

$26→$34

Hold

9.18%

Upside

Reiterated

03/24/25

Alkermes (ALKS) PT Raised to $34 at JPMorganJPMorgan analyst Jessica Fye raised the price target on Alkermes (NASDAQ: ALKS) to $34.00 (from $26.00) while maintaining a Neutral rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$35

Buy

12.40%

Upside

Reiterated

05/31/25

Joseph ThomeTD Cowen

TD Cowen

$38

Buy

22.03%

Upside

Reiterated

06/03/25

TD Cowen Remains a Buy on Alkermes (ALKS)

David AmsellemPiper Sandler

Piper Sandler

$38

Buy

22.03%

Upside

Reiterated

05/29/25

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Ami FadiaNeedham

Needham

$45

Buy

44.51%

Upside

Initiated

05/28/25

Alkermes Poised for Growth with Promising ALKS 2680 and Strategic Pipeline Expansion

Uy EarMizuho Securities

Mizuho Securities

$40

Buy

28.45%

Upside

Reiterated

05/23/25

Mizuho Securities Reaffirms Their Buy Rating on Alkermes (ALKS)

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$42

Buy

34.87%

Upside

Reiterated

05/14/25

Stifel Nicolaus Keeps Their Buy Rating on Alkermes (ALKS)

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

$43

Buy

38.09%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Joel BeattyRobert W. Baird

Robert W. Baird

$38→$41

Buy

31.66%

Upside

Reiterated

05/02/25

Alkermes price target raised to $41 from $38 at BairdAlkermes price target raised to $41 from $38 at Baird

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$46

Hold

47.72%

Upside

Reiterated

05/02/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (NASDAQ: BMRN) and Alkermes (NASDAQ: ALKS)

Jason GerberryBank of America Securities

Bank of America Securities

$35

Hold

12.40%

Upside

Reiterated

05/01/25

Alkermes Hold Rating: Balancing Orexin Program Prospects and Competitive Risks

Marc GoodmanLeerink Partners

Leerink Partners

$30

Hold

-3.66%

Downside

Reiterated

05/01/25

Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (NASDAQ: ALHC), Alkermes (NASDAQ: ALKS) and Summit Therapeutics (NASDAQ: SMMT)

Leonid TimashevRBC Capital

RBC Capital

$39→$40

Hold

28.45%

Upside

Reiterated

05/01/25

RBC Capital Keeps Their Hold Rating on Alkermes (ALKS)

Ashwani VermaUBS

UBS

$38→$33

Hold

5.97%

Upside

Reiterated

04/28/25

Alkermes price target lowered to $33 from $38 at UBSAlkermes price target lowered to $33 from $38 at UBS

David HoangDeutsche Bank

Deutsche Bank

$40→$52

Buy

66.99%

Upside

Reiterated

03/27/25

Alkermes price target raised to $52 from $40 at Deutsche BankAlkermes price target raised to $52 from $40 at Deutsche Bank

Jessica FyeJ.P. Morgan

J.P. Morgan

$26→$34

Hold

9.18%

Upside

Reiterated

03/24/25

Alkermes (ALKS) PT Raised to $34 at JPMorganJPMorgan analyst Jessica Fye raised the price target on Alkermes (NASDAQ: ALKS) to $34.00 (from $26.00) while maintaining a Neutral rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

1 Month

xxx

Success Rate

9/14 ratings generated profit

Average Return

+4.56%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +4.56% per trade.

3 Months

xxx

Success Rate

12/14 ratings generated profit

Average Return

+8.24%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +8.24% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

13/14 ratings generated profit

Average Return

+24.69%

reiterated a buy rating 28 days ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +24.69% per trade.

2 Years

xxx

Success Rate

19/19 ratings generated profit

Average Return

+17.41%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +17.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 10 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 39.79.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is $0.39 with a range of $0.20 to $0.52. The previous quarter’s EPS was $0.13. ALKS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year ALKS has Preformed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $343.23M with a range of $327.19M to $360.02M. The previous quarter’s sales results were $306.51M. ALKS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year ALKS has Preformed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes’s 12-month average price target is 39.79.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes has 27.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes has a consensus rating of Moderate Buy which is based on 8 buy ratings, 6 hold ratings and 0 sell ratings.

What is Alkermes’s price target?

The average price target for Alkermes is 39.79. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $30.00. The average price target represents 27.78% Increase from the current price of $31.14.

What do analysts say about Alkermes?

Alkermes’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts